Comparative Pharmacology
Head-to-head clinical analysis: ALINIA versus HYDROXYSTILBAMIDINE ISETHIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALINIA versus HYDROXYSTILBAMIDINE ISETHIONATE.
ALINIA vs HYDROXYSTILBAMIDINE ISETHIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitazoxanide is a thiazolide antiparasitic agent that inhibits the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction, which is essential for anaerobic energy metabolism in parasites.
Hydroxystilbamidine isethionate is an antiprotozoal agent that inhibits nucleic acid synthesis and disrupts polyamine metabolism by binding to DNA and RNA, particularly in kinetoplasts of Leishmania species.
500 mg orally twice daily for 3 days, with food.
2-4 mg/kg/day intravenously every 24 hours for visceral leishmaniasis; 2-4 mg/kg intramuscularly every 24 hours for cutaneous leishmaniasis.
None Documented
None Documented
Terminal half-life of tizoxanide is approximately 1.5-2 hours in patients with normal renal function; clinical context: short half-life requires twice-daily dosing.
Terminal half-life: 24-48 hours; clinically, elimination is multiphasic with a slow tissue redistribution phase, requiring cautious dosing to avoid accumulation.
Fecal (75-85% as tizoxanide), renal (5-10% as tizoxanide and conjugates), biliary (minor).
Renal: 10-15% as unchanged drug; biliary/fecal: 80-90% as metabolites and unchanged drug; negligible glomerular filtration due to high protein binding; prolonged presence in tissues.
Category C
Category C
Antiprotozoal Agent
Antiprotozoal Agent